Sandoz Stung By The US Again As Sales And Margins Fall In Q3

Sales Fall By 20% In US As Product Mix Impacts Core Operating Margin

 
• By Dean Rudge

As parent Novartis announced plans for a strategic review for its Sandoz business, the generics and biosimilars unit posted falling sales again for the third quarter of 2021, after championing stability in Q2. Sandoz is banking on biosimilars to return to growth.

Waves crashing against the shoreline at sunset along the Western coast of Oahu
Another quarter of declines was reported by Sandoz after stability in Q2 • Source: Alamy

More from Earnings

More from Business